Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

In the News
Greg Scott presents industry update during JPMorgan
>> View video…

>> More News...

Now on Twitter!
 

Twitter ID: ChinaBio

China Aoxing Given OK for Trial of Narcotic Drug

publication date: Sep 17, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

China Aoxing Pharmaceutical Company received SFDA approval to begin a clinical trial of Tilidine/Naloxone capsules, a narcotic drug for moderate to severe pain. The drug is given to alleviate cancer and post-surgical pain. China Aoxing plans to begin the clinical trial by the end of this year, and expects to receive final approval of the drug in 2011. As a Class III New Medicine, it will be given at least three years of market exclusivity protection following SFDA approval. More details...

Stock Symbol: (OTCBB: CAXG)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
ChinaBio® Events
April 14, 2010
Guangzhou, China

SEED Final Competion and Award Ceremony
April 23, 2010
Shanghai, China
Suzhou, China
June 23-24, 2010
 
Partner Events

China 2010 Pharmaceutical R&D Summit
Shanghai, China
April 5-8, 2010

Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners